Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.

Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM, Warnke RA, Natkunam Y, Han SS, Yuen A, Plevritis SK, Advani RH.

Blood. 2013 Aug 8;122(6):981-7. doi: 10.1182/blood-2013-03-491514. Epub 2013 Jun 18.

2.

A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.

Sigal BM, Munoz DF, Kurian AW, Plevritis SK.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1066-77. doi: 10.1158/1055-9965.EPI-12-0149. Epub 2012 May 3.

3.

A simulation model investigating the impact of tumor volume doubling time and mammographic tumor detectability on screening outcomes in women aged 40-49 years.

Bailey SL, Sigal BM, Plevritis SK.

J Natl Cancer Inst. 2010 Aug 18;102(16):1263-71. doi: 10.1093/jnci/djq271. Epub 2010 Jul 27.

4.

Incidental extracardiac findings at coronary CT: clinical and economic impact.

Lee CI, Tsai EB, Sigal BM, Plevritis SK, Garber AM, Rubin GD.

AJR Am J Roentgenol. 2010 Jun;194(6):1531-8. doi: 10.2214/AJR.09.3587.

5.

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.

Kurian AW, Sigal BM, Plevritis SK.

J Clin Oncol. 2010 Jan 10;28(2):222-31. doi: 10.1200/JCO.2009.22.7991. Epub 2009 Dec 7.

6.

Modeling the transition of lung cancer from early to advanced stage.

Pashkevich MA, Sigal BM, Plevritis SK.

Cancer Causes Control. 2009 Nov;20(9):1559-69. doi: 10.1007/s10552-009-9401-4. Epub 2009 Jul 23.

PMID:
19629730
7.

A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000.

Plevritis SK, Sigal BM, Salzman P, Rosenberg J, Glynn P.

J Natl Cancer Inst Monogr. 2006;(36):86-95.

PMID:
17032898
8.

Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.

Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM.

JAMA. 2006 May 24;295(20):2374-84.

PMID:
16720823
9.

A natural history model of stage progression applied to breast cancer.

Plevritis SK, Salzman P, Sigal BM, Glynn PW.

Stat Med. 2007 Feb 10;26(3):581-95.

PMID:
16598706
10.

Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk.

Kurian AW, Mills MA, Jaffee M, Sigal BM, Chun NM, Kingham KE, Collins LC, Nowels KW, Plevritis SK, Garber JE, Ford JM, Hartman AR.

Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1082-9.

11.

Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens.

Stamey TA, Yemoto CM, McNeal JE, Sigal BM, Johnstone IM.

J Urol. 2000 Apr;163(4):1155-60.

PMID:
10737486
12.

Biological determinants of cancer progression in men with prostate cancer.

Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM.

JAMA. 1999 Apr 21;281(15):1395-400.

PMID:
10217055

Supplemental Content

Loading ...
Support Center